Guangxi LiuYao Group (603368) Fair Value & Analysis
Healthcare · CN · Market cap 6.6B CNY
Fair value as of: Jul 24, 2026
From 26 valuation models · updated 17 days ago
Share price +2.3% over the past month.
A solid business, screening 151% undervalued on our models.
What matters now
- The price is below even our cautious bear case (¥29.47). The market is more pessimistic than our downside scenario.
- Solid quality (50/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 24, 2026.
How to read this chart
60‑month range ¥13.11 – ¥25.22 · fair‑value band ¥29.47 – ¥49.12 · the ¥15.63 price screens below the ¥39.29 fair value. Dashed = 300-day average. As of Jul 24, 2026.
Analysis
Guangxi LiuYao Group (603368) currently trades at ¥15.63, while our model-based Fair Value estimate is ¥39.29, implying the stock looks roughly 151.4% undervalued today. The Quality Score stands at 50/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Guangxi LiuYao Group generated revenue of 21.0B CNY at a net margin of 3.1%. Revenue grew 1.1% year over year. It earns a return on equity of 8.1%. Net debt stands at 393M CNY. Fundamentals as of Jul 24, 2026
Our scenario range runs from ¥29.47 (bear case) to ¥49.12 (bull case); at ¥15.63, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 25% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at 151%, 603368 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥53.08) versus Asset-Based (¥13.21). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 24, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 51 · Market factors (momentum, volatility) 42
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Guangxi LiuYao Group Co., Ltd engages in the wholesale and retail of pharmaceutical products in China. It offers various types of medicines, medical devices, consumables, and test reagents through online pharmacies and terminal physical pharmacies. The company was founded in 1981 and is based in Liuzhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Guangxi LiuYao Group reported revenue of ¥20.9B in FY2025 versus ¥17.1B in FY2021, a compound +5.1%/yr. Reported net income was ¥709M in FY2025, compounding +5.9%/yr from FY2021.
Watch 603368: get an alert when its fair value changes →
Peer Group
Medical Distribution · 81 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $805.96 | $819.31 | +2% |
| Cencora, Inc COR | $303.44 | $175.74 | -42% |
| Cardinal Health, Inc CAH | $224.94 | $141.77 | -37% |
| Henry Schein, Inc HSIC | $87.82 | $74.67 | -15% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.70 | ¥33.96 | +103% |
| Sinopharm Group 1099 | HK$16.74 | HK$61.33 | +266% |
| Galenica AG GALE | CHF 87.05 | CHF 61.79 | -29% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.50 | ¥28.65 | +33% |
| Jointown Pharmaceutical Group 600998 | ¥4.99 | ¥9.84 | +97% |
| Asker Healthcare Group ASKER | kr 79.45 | kr 25.69 | -68% |
Compare Guangxi LiuYao Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Guangxi LiuYao Group (603368) overvalued or undervalued?
What is the fair value of 603368?
What is the quality score of 603368?
What is the revenue of Guangxi LiuYao Group (603368)?
What is the net profit margin of 603368?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Guangxi LiuYao Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.